Clinical Trial Update: Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 2]

View source ↗

Summary

This Phase 2 study evaluated the safety and efficacy of adalimumab for moderate-to-severe chronic plaque psoriasis. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: Abbott | Conditions: Psoriasis | Phase 2 | Status: COMPLETED